Lakefront Biotherapeutics American Depositary Shares
LKFT
85 hedge funds and large institutions have $746M invested in Lakefront Biotherapeutics American Depositary Shares in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 35 reducing their positions, and 20 closing their positions.
245% more call options, than puts
Call options by funds: $6.93M | Put options by funds: $2.01M
2.31% less ownership
Funds ownership: 17.23% → 14.93% (-2.3%)
8% less funds holding
Funds holding: 92 → 85 (-7)
30% less capital invested
Capital invested by funds: $1.06B → $746M (-$313M)
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
43% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 35
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$21.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.3M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$6.37M |
| 4 |
DM
Deerfield Management
New York
|
+$2.87M |
| 5 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$44M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$36.5M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$21.5M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$14.4M |
| 5 |
Jane Street
New York
|
-$13.3M |
LKFT Hedge Fund Activity: Q4 2018 in Review
85 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q4 2018, worth a combined $746M — down 30% from $1.06B a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of LKFT and 14 opened new positions — a net loss of 6 holders — while 35 trimmed existing stakes and 20 added.
The largest buyer was Bank of New York Mellon, adding an estimated $21.3M. The largest seller was OrbiMed, exiting entirely with an estimated $44M sold.
- 85 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q4 2018, down from 92 in Q3 2018.
- Funds reported $746M of Lakefront Biotherapeutics American Depositary Shares stock for Q4 2018, down 30% quarter-over-quarter.
- 14 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q4 2018 and 20 closed out, a net change of -6 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q4 2018 was Bank of New York Mellon, an estimated $21.3M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q4 2018 was OrbiMed, an estimated $44M sold.
Based on aggregated 13F filings for Q4 2018.